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Keratinocytes can function as antigen-presenting 
cells/accessory cells and regulate T cells with three 
distinct outcomes, depending on the nature of the 
stimulus. In the presence of alloantigen, it appears 
that a "null" event takes place between T cells and 
keratinocytes, with neither activation nor induction 
of tolerance. Using nominal antigen, keratinocytes 
induce antigen-specific tolerance. In contrast, with 
bacterial-derived superantigens, phytohemaggluti­
nin, or immobilized CD3 monoclonal antibody, ke­
ratinocytes can significantly activate resting autolo­
gous T-cell proliferation and cytokine release. To 
understand these highly divergent responses, we fo­
cused on the two-signal model of T-cell activation, 
with particular emphasis on co stimulatory molecules 
expressed by keratinocytes. Such second signals, as 
highlighted by the B7 and CD28 receptor families, 
SELECTIVE RECRUITMENT AND LOCAL ACTIVATION 
OF T CELLS IN THE SKIN 
The skin is frequently the site of numerous immune-mediated 
disease processes that involve prominent infiltration by T lympho­
cytes. During the past several years, much has been learned 
regarding the molecular basis for T-cell trafficking in normal and 
diseased skin, with particular emphasis on the role of adhesion 
molecules [1]. Indeed, it is currently accepted that numerous 
ligand-receptor interactions can be operative at multiple sites 
(reviewed in [2,3]). With the recognition of skin-seeking T-cell 
subsets [4] and the nonrandom migration pattern ofT cells into the 
skin mediated by adhesion molecules [5], attention was directed at 
exploring how T cells become activated to proliferate once they 
enter epidermal and dermal compartments. Our principal conten­
tion is that T-cell activation and proliferation occur after selective 
recruitment of resting T cells within skin, rather than by nonspecific 
infiltration ofT cells activated elsewhere, which passively enter the 
skin [6]. Based on this premise, we can ask: What is the molecular 
basis for T-cell activation/proliferation? 
To answer this question, we have relied heavily on advances 
made by cellular immunologists working in areas outside of der­
matology. There are many complex signaling mechanisms that 
regulate T-cell activation and proliferation. This should not be 
surprising, as many fundamentally important responses are gov-
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provide useful insights into the complex interactions 
involving keratinocytes and T cells. In this review, we 
summarize recent evidence indicating that keratino­
cytes regulate T-cell activation in a direct and indi­
rect manner by .their mutual expression and respon­
siveness involving adhesion molecules, cytokines, 
and costimulatory signals. As investigative momen­
tum continues to grow in the fields of immunology 
and keratinocyte biology, it is likely that manipUla.., 
tion of CD28:B7 interactions will not only provide a 
useful model to understand further the complexities 
of skin immune reactions, but will also serve as the 
basis for new therapeutic opportunities for numerous 
T -cell-mediated diseases that involve aberrant reac­
tions with keratinocytes. Key words: CD28:B7 costimu­
lation/skin disease/superantigen/cytokines. J Invest Dermatol 
105:25S-29S,1995 
emed by T-cell activation, including induction and maintenance of 
central and peripheral tolerance and immune responses to infec­
tious agents, exogenous allergens, tumor antigens, etc. [7]. A 
review of all of these topics cannot be presented herein; rather, we 
highlight one specific regulatory event involving the role of 
antigen-presenting cells (APCs) in T-cell activation in normal and 
diseased skin. In the past, most investigators were involved with 
defining the number , distribution, and type of lymphocytes (Le., 
helper/inducer versus cytotoxic/suppressor; CD4 versus CD8 ; naive 
versus memory; TH1 versus TH2, etc.) rather than the type of APC 
that accompanies the T-cell infiltration. We take a more proximal 
perspective, suggesting that the APC is the key factor that directs 
and regulates whether and how T cells respond to exogenous or 
endogenously derived antigens responsible for initiating skin im­
mune reactions. 
HISTORIC PERSPECTIVE FROM A DERMATOLOGIC 
VIEWPOINT ON REGULATION OF T-CELL ACTIVATION 
Immunodermatologists initially seized upon the two-step model for 
T-cell activation by focusing on the role of constitutive human 
leukocyte antigen (HLA)-DR expression by epidermal Langerhans 
cells and the role of keratinocyte-derived epidermal thymocyte­
activating factor [8]. As most investigators recognized at the time, 
Langerhans cells were portrayed as acquiring antigen and express­
ing it to appropriate T cells in the context ofHLA-DR. However, 
it was recognized early that this so-called signal 1 required an 
additional signal if T-cell proliferation was to follow, and this was 
portrayed as being delivered in the form of a soluble signal 2 (i.e., 
interleuldn-l [IL-l] [9]). This two-step model was gratifying 
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because it suggested an immunologic dialogue involving three 
different cell types that was often seen in anatomic juxtaposition: 
Langerhans cells:keratinocytes:T cells. From this vantage, kerati­
nocytes were promoted from their previously unappreciated immu­
nocytic function as a passive/inert target of immune-mediated 
diseases to an active participant producing the critical cytokine 
IL-1. 
Even though T-cell antigen receptor (TCR) occupancy is nec­
essary, T-cell proliferation will not occur in the vast majority of 
normal T cells unless a costimulus is also present. For dermatolo­
gists interested in studying T-cell activation, the situation is frus­
trating if one dwells on signal 1 only because the nature of the 
antigen in many T-cell-mediated diseases is unknown. However, 
by focusing on co stimulatory signals, investigators gained several 
valuable new insights with implications beyond skin disease. Before 
delving into these new discoveries, we will briefly review the roles 
of cytokines and non-cytokines in providing co stimulation. It has 
been established that IL-l can function as a costimulatory molecule 
(signal 2) in some murine IL-4-producing CD4 T-cell clones [10]. 
However, it is becoming clear that IL-l or other keratinocyte­
derived cytokines cannot provide signal 2 for many different types 
of IL-2-producing T-cell clones [11]. Such TH-l-type cells (which 
have been implicated in psoriasis, for example [12,13]) require 
something different from a soluble cytokine to be present when 
signal 1 is delivered to the CD3/TCR to the resting T lymphocytes. 
This alternate signal 2 is present in the form of a cell-surface 
adhesion molecule on an APC, rather than as a secreted soluble 
cytokine. The best-characterized co stimulatory system involved in 
APC:T-cell interaction is mediated by B7:CD28 (reviewed in [14]). 
We are not suggesting that cytokines are not important, but they 
probably act in a more distal fashion, and together with more 
proximal signaling events involving surface molecules, provide the 
most comprehensive way of understanding the complex multistep 
process for optimal T-cell activation. 
The CD28 molecule is a member of the immunoglobulin gene 
superfamily that is expressed by 95% of CD4+ T lymphocytes and 
52% of CD8+ T lymphocytes obtained from human peripheral 
blood [15]. When the CD28 molecule becomes engaged, a unique 
signal-transduction pathway synergistically interacts with TCR/ 
CD3 receptor stimulation to produce maximal cell proliferation and 
lymphokine secretion [14]. An important advance in understanding 
the role of CD28 in T-cell function occurred when CD28 ligand 
was identified [16]. Two antibodies were initially used to detect the 
CD28 ligand (i.e., B7 and BB-l), and were widely believed to bind 
to an identical epitope [17,18]. However, as described in the next 
section, it is now appreciated that there are multiple CD28 ligands, 
referred to as B7-1 (previously known as B7; CD80), B7-2 (CD86), 
and B7-3 (previously labeled BB-l) [19,20]. It has been suggested 
that B7-2 may be a more relevant stimulatory ligand for CD28 than 
is B7-1 [21-23]. 
STUDIES OF KERATINOCYTES AS APCs REVEAL 
DISCORDANT PATTERNS OF EXPRESSION OF 
B7-1 AND B7-3 
Our interest in the APC function of keratinocytes actually dates 
back a decade to the original observation that although interferon­
gamma (IFN-y) could induce keratinocytes to express HLA-DR 
and HLA-DQ, these same keratinocytes failed to stimulate a 
significant allogeneic T-cell proliferative response [24]. This sur­
prising negative result was confirmed by several other groups and 
suggested that keratinocytes may lack the capacity to provide an 
appropriate second signal to complement the initial delivery of 
alloantigen signal 1 in the context of IFN-y-inducible major 
histocompatibility complex (MHC) class II molecules. Thus, we 
obtained a full-length eDNA probe for B7-1 (provided by Dr. Lee 
Nadler, Boston, MA) and used Northern blot hybridization to 
examine cultured keratinocytes that had been activated by a wide 
variety of cytokines and a tumor promoter, 12-0-tetradecanoyl­
phorbol-13 acetate (TPA), without induction of a B7-1 transcript 
[25]. As part of these studies, we used antibodies to detect the 
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proteins B7-1 and B7-3. Using several different antibodies against 
B7-1, we found no significant expression by keratinocytes, either in 
vitro or in vivo, confirming the mRNA analysis [25]. However, 
using the anti-BB-l antibody, we noted several differences in the 
pattern of B7-3 expression. First, cultured keratinocytes exposed to 
IFN-y alone increased B7-3 expression, with further enhancement 
seen by combining IFN -y plus TP A, as detected by flow cytometry. 
Second, in vivo immunostaining revealed that normal human skin 
epidermal keratinocytes did not stain, but psoriatic plaques con­
tained B7-3-staining keratinocytes. Third, thymic epithelial cells 
also stained for B7-3. These latter results suggested that B7-3 was 
different from B7-1 and raised the question as to whether BB-l 
keratinocytes were capable of recognizing or mediating binding via 
CD28. 
To address this issue, we performed adhesion assays in which 
keratinocytes expressing BB-l were overlaid on COS7 cells that 
had been either mock transfected or transfected with CD28. The 
results were clear: keratinocytes would bind only to the CD28-
positive COS7 cells (and not to the mock transfectants), and this 
binding was inhibited only by antibodies against CD28 or BB-l, but 
not against B7-1. Thus, we concluded that B7-1 and B7-3 were not 
identical, as had been thought previously, and that keratinocytes 
could express a cell-surface molecule capable of recognizing CD28. 
On one hand, it appeared that the lack of allostimulating capacity of 
keratinocytes could be related to their lack of B7-1, but on the 
other hand, the immunologic significance of B7-3 expression was 
unclear. The next series of experiments was initiated to reexamine 
the APC function of keratinocytes with a particular emphasis on the 
CD28:B7 pathway. In the following two sections, we review the 
results for each set of experiments, beginning with the immuno­
logic consequences of B7-1 expression by keratinocytes and in the 
second section examining the APC capacity of keratinocytes. 
TRANSFECTION OF B7-1 INTO KERATINOCYTES 
To prove that the lack of alloantigen reactivity of keratinocytes was 
due to an absence of signal 2 (i.e., B7-1), we transfected an 
immortalized keratinocyte cell line (HaCat) with B7-1 and deter­
mined the allostimulatory capacity of these cells before and after 
IFN-y exposure.t Cells were transfected with a B7-1 vector, and 
the B7-1-expressing cells were sorted by flow cytometry after a 2-d 
incubation with IFN-y (Fig 1). Thus, the cells of interest were B7-1 
positive and expressed class II MHC antigens and intercellular 
adhesion molecule-l (ICAM-l). Compared with mock_transfected 
cells, B 7 -I-positive cells provoked an allogeneic T-cell response, 
but this reaction was not particularly dramatic when compared with 
other mixed lymphocyte reactions (MLRs) using monocytes/mac­
rophages or dendritic cells. A typical result is shown in Fig 2. It 
should be noted that very similar results were observed indepen­
dently with different cell lines [26]. We have continued to try to 
determine why these B7-1-positive keratinocytes were not partic­
ularly potent in MLRs and proposed that they may have possessed 
even more potent allostimulatory capacity if we could have done 
the following: 1) neutralize the IL-I0 they produce, which inhibits 
the MLR; 2) transfect in the more potent CD28 ligand B7-2 rather 
than B7-1; 3) transfect in the invariant chain (CD74) used for 
processing of class II MHC-associated peptides [27,28]; and 4) 
further enhance their class II MHC levels, as a previous report 
described relatively low levels of HLA-DR expressed after IFN-y 
treatment of keratinocytes compared with professional APCs [29]. 
We now tum from the issue of lack of alloreactivity to autologous 
keratinocyte:T -cell interactions. 
KERATINOCYTES CAN FUNCTION AS APCs USING 
SEVERAL DIFFERENT T-CELL MITOGENS 
To examine the possible APC role for B7-3 on keratinocytes, we 
asked whether they could serve as accessory cells, in which T-cell 
t NickoloffBJ, Mitra RS, Turka LA: Transfection ofCD28 ligand B7-1 
and anti-IL-10 mAb are important for allogeneic T cell response to IFN-')' 
treated keratinocytes (abstr). ] Invest Dermatol 102:583, 1994. 
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Figure 1. Keratinocytes can be transfected to express B7-1. Flow 
cytometric profile of IFN--y-treated (500 U/ml; 48 h) keratinocytes ana­
lyzed for B7-1 expression. Before transfection (dashed line), keratinocytes 
are devoid ofB7-1 cell-surface expression. However, after cotransfection 
using a full-length cDNA ofB7-1 as well as a neomycin resistance gene, and 
positive selection, a uniform population of B7-1-positive keratinocytes 
(solid line) was obtained. These IFN--y-treated, B7-1-transfected cells were 
also strongly positive for HLA-DR and ICAM-1 (data not shown). 
signal 1 was provided by either phytohemagglutinin (PHA) , bac­
terial-derived superantigens, or immobilized CD3 monoclonal 
antibody (MoAb) [30]. Compared with the inability of allogeneic 
IFN--y-treated keratinocytes to provoke a strong allostimulatory 
reaction and the tolerogenic capacity ofkeratinocytes with nominal 
antigen [31,32], there was vigorous T-cell proliferation when T 
cells were incubated with either PHA, superantigens, or immobi­
lized anti-CD3 MoAb in the presence of IFN--y-treated keratino­
eytes. Our primary focus was staphylococcal enterotoxins A and B 
because of the association between bacterial infection and psoriasis 
[33]. Such bacterial-derived superantigens provided a plausible 
association between infection in the pharynx or at other extracu­
taneous sites and skin eruptions mediated by T cells. Superantigens 
by themselves cannot activate T cells, but when IFN--y-treated 
keratinocytes are added, T-cell proliferation and cytokine release 
ensue [30,34). Using various blocking reagents, it was determined 
that this T-cell stimulation was mediated primarily by LFA-1: 
ICAM-1 interaction. In fact, none of the T-cell proliferation 
observed using keratinocytes as accessory cells was influenced by 
inhibitory reagents targeting the B7-1:CD28 molecules. This led us 
to suggest that the B7-3 expressed by keratinocytes may either play 
no role or may provide a nonstimulatory signal that is overcome by 
the positive signal generated via either LFA-l:ICAM-1 or LFA-2: 
LFA-3 interactions. 
Another currently unresolved issue involves the nature of the 
second signal provided by the keratinocytes when T cells have 
signal 1 delivered via PHA, immobilized anti-CD3 MoAb, or 
superantigens . The lack of involvement of the CD28:B7 family of 
molecules implies the existence of additional costimulatory path­
ways, and we are currently characterizing such molecular interac­
tions. Because keratinocytes can mediate antigen-specific tolerance 
[31,32], it is possible that modifications are needed to the current 
dogma that long-standing unresponsiveness to nominal antigen is 
due to delivery of signal 1 without signal 2 [10,11). Our modifica­
tion would include consideration of a model in which signal 1 
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Figure 2. B7-1-transfected keratinocytes stitnulate an allogeneic 
T-cell proliferative response that is greater than that of mock­
transfected B7-1-negative keratinocytes. T cells, 5 X 10\ were 
combined with either PHA (to confirm purity of negative-selection proce­
dure with removal of all accessory cells) or with various numbers of 
allogeneic stimulator cells, as described previously [30]. IFN--y-treated 
HaCat cells (500 U/ml; 48 h) were positively sorted using an Epics V Bow 
cytometer (see Fig 1) and combined with responder T cells. Note that tht 
B7-1-transfected keratinocytes significantly stimulated (p < 0.01) alloge­
neic T cells to proliferate (6-d coculture; 1 JLCilwell 3H-thymidine added 
for final 6 h before harvesting and liquid scintillation counting) when used 
at either 1 X 103,5 X 10', or 1 X 104 cells/well. In contrast, no significant 
(p > 0.05) allogeneic T-cell proliferation was seen using the IFN--y-treated, 
B7-1-negative HaCat cells. Note that when 4 X 10' irradiated allogeneic 
Ficoll-Hypaque interface peripheral blood mononuclear cells (PBMCs) 
were used as stimulators, a much stronger MLR was observed compared 
with the keratinocyte reactions. T-cell proliferation data (±SD) are repre­
sentative of three independent experiments. 
(being nominal antigen) is followed by an inappropriate or nonac­
tivating signal 2 (i .e. , via B7-3 rather than B7-1 or B7-2), which 
would result in a functional state of anergy or tolerance. Recent 
unpublished observations by Dr. Lee Nadler at the Dana Farber 
Cancer Institute (Boston, MA) have demonstrated the existence of 
a non-B7-1 or -B7-2 molecule that can actually trigger apoptosis in 
an antigen-specific manner [35]. Work is currently in progress to 
determine whether keratinoeyte B7-3 can mediate programmed 
cell death of specific subsets of T cells. In any event, it should be 
clear that new insights into T-cell activation have been derived 
from studies designed to address costimulatory signaling pathways 
involving keratinocyte:T-cell interactions [28]. 
In studies of bacterial-derived superantigens and keratinocytes, 
the T-cell response was found to resemble most closely a 'IH-2-
type cytokine production profile, with high levels ofIL-4, IL-5, and 
IL-10, but not IFN--y [34]. With recognition of the importance of 
IL-12 in generating a 'IH-1-type response [36], it was necessary to 
determine whether keratinocytes could produce IL-12. By reverse 
transcriptase-polymerase chain reaction analysis, resting or acti­
vated cells were found to express the p35 mRNA species ofIL-12 
but not the inducible p40 mRNA species , and no functional protein 
was detected in the supernatant by a sensitive enzyme-linked 
immunosorbent assay [34]. However, if as little as 1 ng/ml of 
recombinant human IL-12 was added to the superantigen-driven 
T-cell response in the presence of keratinocytes, approximately 
2-9-fold higher levels of IFN--y were produced. Moreover, when 
professional APCs (i.e., dermal dendritic cells or blood-derived 
macrophages) were used rather than the nonprofessional APCs 
(i.e., keratinocytes), with the same superantigens and the same 
responder population of T cells, high levels of IFN--y were pro­
duced with little or no IL-4, IL-5, or IL-I0 [37]. Another group has 
observed that the presence or absence ofB7 on the APCs dictated 
whether a TH-l-type or TH-2-type cell response was produced 
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[38]. Thus, the qualitative nature of the T-cell response (TH-1 
versus TH-2) was significantly influenced by the presence or 
absence of IL-12 and by the type of APC used in providing 
co stimulating signals [28]. Cultured dermal dendritic cells can 
produce IL-12 mRNA, as detected by reverse transcriptase-poly­
merase chain reaction (Nestle Fa, Nickololf Bj, unpublished 
results), and apparently so can epidermal Langerhans cells.:!: IL-12 
is also important because it can synergize with B7:CD28 interac­
tions in the promotion of T-cell proliferation and cytokine release 
[39,40]. All of the available data support the view that proximal 
molecular events involve direct cell-cell interaction between T cells 
and APCs, mediated by CD3/TCR and costimulatory pathways, 
followed by the modulatory and more distal elfects of cytokines that 
are present in the local microenvironment. 
SUMMARY 
Once a resting blood-derived T lymphocyte enters the skin, it 
comes within the immunologic sphere of influence [41] of several 
endogenous and recruited cell types, including keratinocytes, den­
dritic cells, and macrophages. Each of these APCs can regulate or 
determine whether the T cell becomes activated or tolerogenized 
by distinctive expression of various cell-surface molecules and 
cytokines. Given the available techniques for isolation and charac­
terization of each individual APC:T -cell reaction in vitro, we can 
begin to determine hierarchic patterns of costimulatory molecule 
expression and cytokine production profiles. Although our current 
understanding of cutaneous T-cell interactions is incomplete, it is 
clear that keratinocytes function quite dilferently from professional 
APCs in their interaction with T lymphocytes [28]. Such interac­
tions are dependent on several variables, including the nature of the 
antigen (alloantigen, nominal, or superantigen), the presence or 
absence of cytokines such as IL-10 or IL-12, and the nature of the 
costimulatory molecular pathway used to deliver signal 2 (CD28 
interaction with either B7-1, B7-2, or B7-3). In ongoing studies, it 
appears that even within professional APC subsets such as macro­
phages and dendritic cells, important dilferences can be detected in 
relative levels of expression of costimulatory molecule and cytokine 
release. For example, keratinocytes express B7-3, but not B7-1 or 
B7-2, and they can produce IL-10 but not IL-12. Dermal dendritic 
cells produce high levels of B7-2 with lower levels of B7-1, and 
these CD28 ligands are dilferentially regulated in both a positive 
and negative fashion by various cytokines, such as tumor necrosis 
factor-a, granulocyte macrophage-colony-stimulating factor, IL-4, 
and IL-10 [42]. On the other hand, macrophages express much 
lower levels ofB7-2 compared with dermal dendritic cells and also 
produce IL-10. Figure 3 summarizes the key dilferences with 
respect to co stimulatory molecule expression and cytokine produc­
tion profile. 
In conclusion, it is clear that keratinocytes should be added to the 
list of potentially important APC/accessory cells resident in the 
skin. Besides dendritic cells and macrophages, which are present in 
both epidermal and dermal compartments [43], keratinocytes can 
be distinguished by their expression of various adhesion molecules, 
costimulatory molecules, and patterns of cytokines produced upon 
activation. Keratinocytes can therefore directly and indirectly reg­
ulate resting T-cell proliferation and activation, with both positive 
and negative consequences. Compared with professional APCs 
such as Langerhans cells, keratinocytes express lower levels of 
HLA-DR and costimulatory molecules and cannot process anti­
gens, thus indicating that in some circumstances they may be less 
efficient APCs than Langerhans cells. However, given the much 
greater number of keratinocytes compared with Langerhans cells, it 
remains to be determined which APC contributes the most elfective 
T -cell-stimulatory signals and the net result of local T-cell activa­
tion. Our challenge for future studies will be to try to manipulate 
these dilferent APC types in a specific manner to help us further 
* Rook AH, Kang K, Kubin M. Cassin M. Trinchieri G, Lessin SR, 
Cooper KD: IL-12 and protein production by epidermal Langerhans cells 
(abstr). Clin Res 42:23 1 , 1994. 
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Figure 3. T-cell interactions with APes in the skin are complex, 
multifactorial, and bidirectional. The cutaneous sphere of immuno­
logic influence of T lymphocytes by keratinocytes, dendritic cells, and 
macrophages is mediated via dilferential expression of specific co stimulatory 
molecules and cytokines. Once a resting skin-seeking T lymphocyte enters 
the dermis or epidermis, it may become activated by reciprocal interactions 
with various types of APC. Each APC can dilferentially influence the T cell 
after the engagement of the CD3/TCR complex (signal 1) by providing 
distinctive costimulatory molecules (signal 2) and contributing locally 
produced cytokines. Depending on the nature of the stimulus, the type of 
APC, and the local cytokine milieu, there are several dilferent potential 
immunologic outcomes that reflect whether the T cell becomes activated, 
anergized, and/or begins producing TH-1- and TH-2-type cytokines itself. 
The most important signaling pathways are portrayed to emphasize the 
multiplicity of adhesion molecules, co stimulatory molecules, and cytokines 
that have been characterized for these cellular constituents of the dermal 
and epidermal immune systems. 
understand the immunoregulatory circuits that exist to restore 
homeostasis and thereby benefit our patients with T -cell-mediated 
skin disorders. 
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AR40488, and CA63928 (BJN). 
REFERENCES 
1. NickololfBJ: The role of gamma interferon in epidermal trafficking oflympho­
cytes with emphasis on molecular and ceUular adhesion events. Arch Demoatol 
124:1835-1843,1988 
2. Kupper TS: Immune and inflammatory events in cutaneous tissues. Mechanisms 
and speculation. ] Clin Invest 86:1783-1789, 1990 
3. Korn J. Piela-Smith T: Interaction of inunune and connective tissue ceU,. In: 
NickololfBJ (ed.). DemoalI",mune System. CRC Press, Boca Raton. FL. 1993. 
pp 185-208 
4. Picker L. Kishimoto TK. Smith CW, Warnock RA, Butcher EC: ELAM-l is an 
adhesion molecule for skin-homing T cells. Nature 349:796-799. 1991 
5. Butcher EC: The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 
128:1-27, 1986 
6. NickololfBJ, Griffiths CEM: Lymphocyte trafficking in psoriasis: a new perspec­
tive emphasizing the dermal dendrocyre with active denna! recruitment 
mediated via endothelial ceUs foUowed by intraepidermal T -ceU activation. ] 
Invest Dermatol 95 (suppl):34S-37S, 1990 
7. Bretscher P, Cohn M: A theory ofself-nonself discrirnination. Science 169:1042-
1049,1970 
VOL. lOS, NO. I, SUPPLEMENT, JULY 1995 
8. Luger TA, Stadler BM, Katz sr, OppenheimJJ : Epidermal cell derived thymocyte 
activating factor.] ImmunoI127:1493-1498, 1981 
9. Kupper T, Ballard D, Chua AO, McGuire JS, Flood PM, Horowitz MC, 
Langdon R, Lightfoot L, Gubler U: Human keratinocytes contain mRNA 
indistinguishable from monocyte interlenkin-11l and 1 f3 mRNA: keratinocyte 
epidermal cell-derived thymocyte activity factor is identical to interlenkin-1.] 
Exp Med 164:2095-2100, 1986 
10. Weaver CT, Unanue ER: The costimulatory function of antigen-presenting 
cells. Immunol Today 11:49-55, 1990 
11. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional 
clonal inactivation: a costimulatory sigualing pathway determines the outcome 
of T-cell antigen receptor occnpancy. Annu Rev Immunol 7:445-480, 1989 
12. Uyemura K, Yamamnra M, Fivenson DF, Modlin RL, Nickoloff BJ: The 
cytokine network in psoriasis is characterized by aT-helper type 1 cell 
mediated response.] Invest Dennatol101:701-705, 1993 
13. SchlaakJF, Busland M, Jochum W, Hermenn E, Gimdt M, GaJlati H, Bushenfeld 
KHM, F leischer B: T cells involved in psoriasis vulgaris belong to the TH-1 
subset.] Invest DennatoI102:145-149, 1994 
14. June CH, LedbetterJA, Linsley PA, Thompson CB: Role of the CD28 receptor 
in T-cell activation. Immunol Today 11:211-216, 1990 
15. Damle NK, Mohagheghpour N, HansenJA, Engleman EG: Alloantigen-specific 
cytotoxicity and suppressor T lymphocytes are derived from phenotypically 
distinct precursors.] Immunol131:2296-2303, 1983 
16. Linsley PS, Clark EA, Ledbetter JA: The cell antigen, CD28, mediates adhesion 
with B cells by interacting with the activation antigen, B7-BB-1. Proc Natl Acad 
Sci USA 87:5031-5035, 1990 
17. Yokochi T, Holly RD, Clark EA: B lymphoblast antigen (BB-1) expressed on 
Epstein-Barr virus activated B cells, B lymphoblastoid cell lines and Burkitt's 
lymphomas.] ImmunoI128:823-827, 1982 
18. Freeman GJ, Freedman AJ, SegilJM, Lee G, WhitmanJF, Nadler LM: B7, a new 
member of the Ig superfamily with unique expression on activated and 
neoplastic B cells.] ImmunoI143:2714-2722, 1989 
19. Boussiotis VA, Freeman GJ, GribbenJG, Daley J, Gray G, Nadler LM: Activated 
human B lymphocytes express three CTLA-4 counterreceptors that costimu­
late T-cell activation. Proc Natl Acad Sci USA 90:11059-11063, 1993 
20. June CH, BluestoneJA, Nadler LM, Thompson CB: The B7 and CD28 receptor 
families. Immunol Today 15:321-331, 1994 
21. Hathcock KS, Laszlo G, DickIer HB, Bradshaw J, Linsley P, Hode FJ: identifi­
cation of an alternative CTLA-4 ligand costimulating for T cell activation. 
Science 262:905-907, 1993 
22. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, 
Gray GS, Nadler LM: Cloning of B7-2: a CTLA-4 counter-receptor that 
costimulates human T cell proliferation. Science 262 :909 -911 , 1993 
23. Azuma M, Ito D, Yagita H, Okumura K, Phillips JK, Lanier LL, Somoza C: B70 
antigen is a second ligand for CTLA-4 and CD28. Nature 366:76-79, 1993 
24. Nickoloff BJ, Basham TY, Torseth J, Merigan TC, Morhenn VB: Human 
keratinocyte-lymphocyte-reactions in vitro.] Invest DennatoI87:11-18, 1986 
25. NickoloffBJ, Mitra RS, Lee K, Turka LA, Green J, Thompson C, Shimizu Y: 
Discordant expression of CD28 ligands, BB-1 and B-7 on keratinocytes in vitro 
and psoriatic cells in vivo. Am] PathoI142:1029-1040, 1993 
26. Gaspari AA, Ferbel B, Chen Z, Razvi F, Polakowska R: Accessory and 
alloantigen presenting cell function of A431 keratinocytes that stably express 
the B7 antigen. Cell ImmunoI149:291-302, 1993 
KERATINOCYTE-REGULATED T-CELL ACTIVATION 29S 
27. Vole-Platzer B, Majdic 0, Knapp W, WollfK, Hinterberger W, Lechoer K, 
Stingl G: Evidence ofHLA-DR antigen biosyothesis by human keratinocytes in 
disease.] Exp Med 159:1784-1789,1984 
28. Nickoloff BJ, Turka LA: Immuoologic functions of non-professional antigen­
presenting cells. New insights from studies of T-cell interaction with kerati­
nocytes. Immunol Today 15:464-469, 1994 
29. Wikner NE, HuJfJC, Norris DA, Boyce ST, Cary M, Kissinger M, Weston WL: 
Study ofHLA-DR synthesis in cultured human keratinocytes.] Invest Dennatol 
87:559-564, 1989 
30. NickoloffBJ, Mitra RS, GreenJ, Zheng XG, Shimizu Y, Thompson C, Turka 
LA: Accessory cell function of keratinocytes for superantigens. ] Immunol 
1 50:2148-2159, 1993 
31. Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J, Lechler R: 
Antigen presentation of keratinocytes induces tolerance in human T cells. Eur 
] Immunol 20:1893-1987, 1990 
32. Gaspari AA, Katz SI: Induction of in vivo hyporesponsiveness to contact 
allergens by hapten-modified Ia+ keratinocytes.] Immunol 147:4155-4161, 
1991 
33. Leung DYM, Walsh P, Gioms R, Norris DA: A potential role for superantigens 
in the pathogene.is of psoriasi •. ] Invest Dennatol100:225-228, 1993 
34. Goodman R, Nesde F, Naidu Y, Green J, Thompson C, NickoloffBJ , Turka LA: 
Keratinocyte-derived T cell costimulation induces preferential production of 
1L-2 and 1L-4 but not IFN-y.] ImmunoI152:5109-5198, 1994 
35. Caux C, Liu Y-J, BanchereauJ: Recent advances in the study of dendritic cells 
and follicular dendritic cells. Immunol Today 16:2-4, 1994 
36. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM: 
Development of THI, CH4+ T cells through 1L-12 produced by Listeria­
induced macrophage •. Science 260:547-549, 1993 
37. Nesde FO, Turka LA, NickoloffBJ: Characterization of dermal dendritic cells in 
psoriasis: autostimulation of T lymphocytes and induction of TH-1 type 
cytokines.) Clin Invest 94:202-209,1994 
38. Tan P, Anasetti C, HansenJA, Melrose J, Bruovand M, Bradshaw J, Ledbetter 
JA, Linsley PA: Induction of alloantigen-specific hyporesponsiveness in human 
T lymphocytes by blocking interaction of CD28 with its natural ligand 
B7IBB1.] Exp Med 177:165-170,1993 
39. Kubin M, Kamoun M, Trinchieri G: Interlenkin 12 syoergizes with B7/CD28 
interaction in inducitig efficient proliferation and cytokine production of 
human T cells. ] Exp Mea 180:211-222,1994 
40. Murphy BE, Terres G, Macatonia SE, Hsieh C-S, MattsonJ, Lanier L, Mysocka 
M, Trinchieri G, Murphy K, O'Garra A: By and interleukin 12 cooperate for 
proliferation and interferon-y production by mouse T helper clone. that are 
unresponsive to B7 costimulation.] Exp Med 180:223-231,1994 
41. Streilein JW: Speculations on the immunopatbogenesis of psoriasis: T cell 
violation of a keratinocyte sphere of influence.] Invest Dennatol 94 (suppl): 
205S-215S, 1993 
42. Mitra RS, Judge TA, Nesde FO, Turka LA, NickoloffBJ: Psoriatic skin-derived 
dendritic cell function is inhibited by exogenous 1L-10.] ImmunoI154:2668-
2677, 1995 
43. Poulter LW, Campbell DA, Munro C, Janossy G: Discrimination of human 
macrophage. and dendritic cells by means of monoclonal antibodies. Scana] 
Immunol 24:351-357, 1986 
